AI-Driven Health Quotient (HQ), Mental Health Quotient (MHQ),

and Biological Age Quotient (BAQ) Assessment

Daniel Roberts, Ph.D.

A structured, evidence-based assessment tool designed to integrate biological, clinical, behavioral, and lifestyle factors in order to comprehensively evaluate overall health status, mental health, and biological aging.

Lifestyle and Behavioral Factors

Objective patterns of behavior that shape physiological resilience and disease risk.

·         Chronological Age (Years and months):

·         Sex: Male / Female

·         Ancestral Group (select one): European; African;  Asian; Hispanic, other (specify):

·         Country of residence:

·         Years living in current country:

·         Country of birth:

·         Primary language spoken at home:

·         Native (first) Language (specify):

2. Dietary Patterns and Nutrition (Diet Composition and Quality)

Guidelines for Responding

1.    For each “Yes” and “No” option listed below. Select exactly one response.

2.    Select “Yes” if the dietary option currently applies to you.

3.    Select “No” if the option does not apply to you.

4.    Leave both “Yes” and “No” unselected if the item is Not Applicable (NA) to your situation.

Note: Items left unselected will be recorded as not applicable (NA) and will be excluded from scoring and subsequent statistical analysis.

Indicate your primary Dietary Pattern (select all that apply)

·         AI-Driven All-Nutrient Diet: Yes / No

·         Mediterranean diet: Yes / No

·         Vegetarian diet: Yes / No

·         Pescatarian (fish) diet: Yes / No

·         DASH diet : Yes / No

·         Ketogenic diet: Yes / No

·         Western or standard omnivorous diet: Yes / No

·         Other diet(s) or dietary pattern(s) (specify): __

Consumption of Foods according to NOVA Food Classification System

 NOVA Group 1. Frequency of consuming unprocessed or minimally processed foods (e.g., fresh or frozen fruits and vegetables, whole grains, eggs, fresh meat or fish, plain milk or plain yogurt): __ times per week.

NOVA Group 2. Frequency of consuming processed culinary ingredients (e.g.,olive oil, butter, sugar, salt): ___ times per week.

NOVA Group 3. Frequency of consuming processed foods (e.g., white bread, sweetened breakfast cereals, flavored yogurt, refined crackers): __times per week.

NOVA Group 4. Frequency of consuming ultra-processed foods (e.g., soft drinks, packaged snack foods, instant noodles, fast-food items, frozen ready-to-eat meals, processed meat): __ times per week.

Proportion of Ultra-Processed Foods:

·         Percentage of your total weekly food intake that consists of Ultra-processed foods: ___ %

Dietary Supplement Use

·        Current use of dietary supplements (e.g., vitamins, minerals, omega-3 fatty acids, amino acids, etc.): Yes / No

·         If yes, list all supplements taken routinely: __

Diversity of diet

Over the previous seven (7) days, how many distinct food groups were included in your diet? Food groups are defined according to the New American Diet, aligned with MAHA principles, with an emphasis on whole, minimally processed, nutrient-dense foods. Refer to the MAHA-aligned food groups listed below.

·         Total number of food groups consumed:___ food groups

MAHA-Aligned Food Groups

1.    Vegetables – non-starchy (e.g., leafy greens, cruciferous vegetables) and starchy vegetables (e.g., potatoes, sweet potatoes, squash, yams, and corn consumed whole, or on the cob).

2.    Fish and shellfish  (e.g., salmon, sardines, trout; mussels, shrimp, scallops).

3.    Healthy fats and oils  (e.g., extra-virgin olive oil, avocado oil).

4.    Fruits  (e.g., fresh and frozenwithout added sugars, syrups, or artificial preservatives).

5.    Nuts and seeds (e.g., almonds, walnuts; flaxseed, hemp, chia, pumpkin seeds).

6.    Poultry and poultry-derived products (e.g., chicken, turkey, duck; including organs such as hearts and gizzards; limit or exclude sausages, hot dogs, and deli meats).

7.    Legumes  (e.g., beans, lentils, chickpeas, as well as split peas and lupins).

8.    Fermented foods (e.g., yogurt, kefir, sauerkraut, kimchi prepared using traditional methods).

9.    Grains and healthy grain-derived products (e.g., oats, barley, brown rice, wheat; pasta, muesli and porridges made from whole grains).

10. Dairy products (e.g., milk, yogurt, cheeses; minimally processed and unsweetened)

11. Red meats and red-meat-derived products(e.g., beef, pork, lamb, veal, goat; organ meats such as kidneys, tongue, tripe).

12. Herbs, spices, and aromatics  (e.g., garlic, onions, rosemary, oregano).

13. Beverages(e.g., water, mineral water, green tea, herbal tea, coffee in its whole, minimally processed form).

14. Traditional sweeteners (e.g., honey, maple syrup, stevia; limit or exclude refined sugars, artificial sweeteners, and processed syrups).

2. Eating Habits (Behaviors and Routines about Food Intake)

Meal Timing and Regularity

·         Number of days per week meals are consumed at consistent times: __ days per week

·         Number of days per week breakfast is skipped: __ days per week

·         Number of days food is consumed within two (2) hours of bedtime: __ days per week

Meal Frequency and Structure

·        Average number of days per week meals are consumed at consistent times: __ days per week

·        Number of days per week meals are replaced with snacks or caloric beverages: __ days per week

Eating Pace and Attention

·        Average duration of main meals: __ minutes per meal

·         Number of meals per week consumed while distracted (e.g., television, phone, computer): __ meals per week

Contextual and Environmental Factors

·         Number of meals consumed outside the home (e.g., restaurants, take-out, delivery): __ meals per week

·         Number of meals ordered online and delivered at home __ meals per week

Emotional and Stress-Related Eating

·         Number of eating episodes per week occurring in response to stress, anxiety, or low mood: __  episodes per week

·         Other eating habits or routines relevant to food intake (specify): __

3. Education (Objective Factual Numerical Questions)

Highest Level of Education Complete (select all that apply)

·         High school diploma or equivalent: Yes / No

·         Trade certification or vocational diploma: Yes / No

·         Bachelor’s degree (e.g., BA, BSc): Yes / No

·         Master’s degree (e.g., MA, MSc): Yes / No

·         Doctorate or professional degree (e.g., Ph.D., Ed.D., M.D., J.D.): Yes / No

Total Educational Duration of Formal Education

·        Total number of completed years of formal education (from primary school to highest degree: __  years

Informal and Self-Directed Education (Quantifiable)

·         Number of non-degree educational programs completed (e.g., MOOCs, certificate programs, structured online courses): __ programs

·         Number of new subject areas formally studied in the past ten (10) years: __ subjects

Language and Literacy Education

·         Number of languages formally studied for at least one academic year: __ languages

·         Number of languages in which formal reading and/or writing proficiency was attained: __ languages

4. Work and Financial Health

Current Employment Status (select one option)

·         Full-time employment: Yes / No

·         Part-time employment: Yes / No

·         Self-employed: Yes / No

·         Unemployed, seeking work: Yes / No

·         Unemployed, not seeking work: Yes / No

·         Retired: Yes / No

Additional Employment Characteristics

·         Number of hours worked per week (if currently employed): __ hours per week

·         Length of time in current employment status: __  years __  months

Profession and Occupational Characteristics

·         Current job title or primary occupation (e.g., homemaker, stay-home-parent, teacher, farmer, manual laborer, nurse) (specify): __

·         Primary industry or employment sector (e.g., education, healthcare, manufacturing, construction, technology, retail, public service) (specify): __

Occupational Exposure and Demands (factual)

·        Predominantly sedentary occupation: Yes / No

·        Regular manual or physical demanding work: Yes / No

·        Average number of working days per week: __ days per week

Financial Status and Resources  (Income Profile)

·        Net annual income (after taxes), reported in USD, CAD, EUR, or local currency (specify currency): __ per year

·        Number of income sources (e.g., employment, self-employment investments, rental income, pensions, government benefits): __ sources

Retirement Savings Participation (select all that apply)

·         Registered Retirement Savings Plan (RRSP): Yes / No

·         401(k) or equivalent employer-sponsored retirement plan: Yes / No

·         Employer-sponsored defined benefit or defined contribution pension plan: Yes / No

·         Private or individual pension plan: Yes / No

·         Other retirement savings (specify): __

Investment Holdings (No dollar amount required)

·         Stocks (equities): Yes / No

·         Bonds (fixed income securities): Yes / No

·         Mutual funds or exchange-traded funds (ETFs): Yes / No

·         Real estate investments (excluding primary residence): Yes / No

·         Cash or cash-equivalent holdings (e.g., savings accounts, money market funds): Yes / No

·         Other investment holdings (specify): __

Standardized Cognitive Measures (if formally assessed)

·         Intellectual Quotient (IQ) score (e.g., WAIS, WISC, Stanford-Binet): __  (numeric score)

·         Academic achievement score (e.g., WIAT-III or WIAT-4, WJ IV ACH, KTEA-3): __ (numeric score)

·         Emotional Quotient (EQ) score (e.g., MSCEIT, EQ-i): __ (numeric score)

Executive Function and Attention (if formally assessed)

·         Executive Function composite score (e.g., BRIEF, D-KEFS): __ (numeric score or T-score)

·         Attention performance score (e.g., CPT, TOVA): __ (numeric score)

·         Cognitive flexibility score (e.g., Trail Making Test Part B): __ (numeric score or T-score)

·         Planning and organization score (e.g., Tower of London, Tower of Hanoi): __ (numeric score or T-score)

·         Other cognitive or mental performance assessments (specify test name and score): __

Cognitive Function and Performance

·         Attention and concentration difficulties diagnosed by a professional: Yes / No

·         Memory impairment diagnosed by a professional: Yes / No

·         Average duration of sustained attention before a break is required: __ minutes

·         Short-term memory performance (number of unrelated items recalled in a typical recall test, if known): __ items

Learning and Neuro-developmental Conditions (if diagnosed) (select all that apply)

·         Dyslexia (reading and/or writing): Yes / No

If yes, specify subtype(s): __

·         Attention-Deficit/Hyperactivity Disorder (ADHD): Yes / No

·         Dyscalculia (learning disorder affecting mathematics skills): Yes / No

·         Autism spectrum condition: Yes / No

·         Other diagnosed learning or neuro-developmental conditions (specify): __

Lifelong Learning and Cognitive Engagement

·         Number of new skills acquired in the past 12 months (e.g., formal courses, languages, certifications, musical instruments): __ skills per year

Reading, Media Use, and Cognitive Engagement

·         Average weekly time spent reading (e.g., books, articles, or academic or professional materials): __ hours per week

·         Average weekly time spent watching television or streaming media: __ hours per week

·         Average weekly time spent on internet browsing or social media use  :__ hours per week

Daily Movement Activity

·         Average daily step count (measured by pedometer, smartwatch, or phone): __ steps per day

Daily Physical Activity by Intensity

·         Light-intensity activity (e.g., slow walking, light household chores, casual gardening, light occupational tasks): __ minutes per day

·         Moderate-intensity activity (e.g., brisk walking, steady-pace cycling; double tennis or pickle ball, recreational swimming, dancing, physically engaging hobbies like home improvement tasks): __ minutes per day

·        Vigorous-intensity activity (e.g., competitive single tennis or pickle ball, running or jogging, fast cycling, martial arts, aerobics or spin classes): __ minutes per day

Weekly Moderate-Vigorous Physical Activity

·         Total weekly exercise duration (all intensities combined): __minutes per day

Muscle Strengthening and Multimodal Exercise (select all that apply)

·         Resistance or strength training: Yes / No

·         Aerobic or cardiovascular training (e.g., jogging, cycling, brisk walking): Yes / No

·         High-intensity interval training (HIIT): Yes / No

·         Yoga or Pilates: Yes / No

·         Swimming or aquatic exercise: Yes / No

·         Martial arts: Yes / No

·         Other exercise types (specify): __

Activities Consistency and Long-Term Adherence

·        Years of regular exercise participation: __  years

·        Number of weeks per year meeting minimum activities guidelines (≥150 minutes of moderate activity or ≥75 minutes of vigorous activity): __  weeks per year

Physical Fitness Capacity (Measured or Estimated)

·         Resting heart rate (RHR): __beats per minute

·         Grip strength (dominant hand): __ kg

·         Estimated maximal oxygen uptake (VO2 max): __  mL/kg/min

·         Sit-to-stand test (30-seconds protocol): __  repetitions

·         Plank hold duration: __ seconds

Sedentary Behavior and Movement Interruption

·         Average daily sedentary time (sitting or reclining): __ hours per day

·         Longest continuous sitting interval per day: __ minutes

·         Time spent standing or walking during work hours or daily activities: __ hours per day

Physical Limitations Affecting Exercise Capacity

·         No known physical limitations: Yes / No

·         Orthopedic or musculoskeletal condition: Yes / No

·         Cardiovascular limitation: Yes / No

·         Respiratory limitation: Yes / No

·         Neurological or balance-related limitation: Yes / No

·         Other limitations (please specify): __

Current marital or partnership status (select one option)

·         Single: Yes / No

·         Married: Yes / No

·         Common-law or long-term partnership: Yes / No

·         Separated: Yes / No

·         Divorced: Yes / No

·         Widowed: Yes / No

·         Duration of current marital or partner relationship: __  years

·         If separated, divorced, or widowed, number of years since separation, divorce, or bereavement: __ years

Household Composition and Living Arrangement (select all that apply)

·         Living alone: Yes / No

·         Living with spouse or partner: Yes / No

·         Living with dependent children: Yes / No

·         Living with extended family members (e.g., parents, siblings): Yes / No

·         Other living arrangement (specify): __

Household Characteristics

·         Total number of people living in the household: __ persons

·         Number of dependent children residing in the household: __ children

·         Ages of dependent children (list each child with their age): __ years

Household Pets and Animal Exposure

·         Number of pets currently living in the household: __ pets

·         Primary type(s) of pets (e.g., dog, cat, fish) (specify): __

·         Average daily interaction with household pets: __ minutes per day

·         Primary role of pet ownership (e.g., companionship, physical activity Emotional support, working or service animal) other (specify): __

Social Support Network and Relationships

·        Number of close friends or family members available for support in times of need: __ individuals

·         Regular engagement in weekly social interactions (in-person or virtual): Yes / No

·        Frequency of social gatherings attended per month (e.g., with friends, family, community, religious, cultural groups): __  gatherings per month

Social Engagement and Participation

·        Average weekly time spent interacting with immediate or extended family members: __ hours per week

·        Average weekly time interacting with friends or colleagues outside of work: __ hours per week

·        Participation in organized community, volunteer, or group activities: __Yes / No

·        Number of organized community, volunteer, or group activities participated during the past 12 months: __ activities per year

Care giving and Social Responsibilities (Factual indicators)

·         Primary caregiver for dependent children: Yes / No

·         Primary or shared caregiver for elderly or disabled family members: Yes / No

Sleep Duration and Timing

·         Average nightly sleep duration on weekdays: __ hours per night

·         Average nightly sleep duration on weekends: __hours per night

·         Average bedtime (24-hour or 12-hour clock format): __: __

·         Average wake time (24-hour or 12-hour clock format): __ : __

·         Sleep schedule consistency (number of days per week with the same sleep schedule): __ days per week

Sleep Quality and Continuity

·        Sleep efficiency (percentage of time asleep while in bed): __ %

·        Average number of night-time awakenings: __awakenings per night

·        Total minutes awake after sleep onset (WASO): __minutes per night

·        Use of sleep-tracking device (e.g., sleep diary/log, smartwatch, ring, or mobile application): Yes / No

Daytime Rest, Alertness, and Recovery

·         Frequency of daytime naps:__ naps per week

·         Average duration of daytime naps: __ minutes per nap

·         Frequency of daytime fatigue or excessive sleepiness: __  days per week

Work Schedule and Circadian Alignment

·         Primary daytime work (between 7:00 a.m. and 7:00 p.m.): Yes / No

·         Evening or late shift: Yes / No

·         Night shift work: Yes / No

·         Rotating or variable shift schedule: Yes / No

Sleep-Related Substances, Medications, and Exposure

·         Use of over-the-counter sleep aids: Yes / No

If yes, frequency of use: __ times per week

·         Use of melatonin supplements: Yes / No

·         Use of prescription sleep medication or sleep-related supplements Yes / No

If yes, specify: __

Evening Stimulant, Alcohol, and Other Substances Before Sleep

·          Caffeine intake after 5 p.m.: Yes / No

·         Consumption of caffeinated tea after 5 PM: Yes / No

·         Consumption of chocolate or cocoa products after 7:00 PM: Yes / No

·         Consumption of high-sugar foods or desserts within 2 hours of bedtime: Yes / No

·         Use of energy drinks after 3:00 p.m.: Yes / No

·         Alcohol consumption within three (3) hours before bedtime: Yes / No

Tobacco and Nicotine Use: Smoking status (select one)

·         Never smoked (lifetime exposure fewer than 100 cigarettes): Yes / No

·         Former smoker (previous cigarette use; no current use): Yes / No

·         Current smoker (any current cigarette use): Yes / No

Exposure History (current or past)

·         Total years of exposure to second-hand smoking: __ years

·         Total years of smoking (current or past):__ years

·         Average number of cigarettes smoked per day (during periods of regular use): __ cigarettes per day

Use of Other Nicotine-Containing Products (select all that apply)

·         Electronic cigarettes or vaping devices: Yes / No

·         Nicotine pouches, lozenges, or gum (non-therapeutic use): Yes / No

·         Chewing tobacco or snuff: Yes / No

Alcohol Use (Current Drinking Status) (select one option)

·         Never drinker: Yes / No

·         Former drinker (no current alcohol use): Yes / No

·         Current drinker: Yes / No

Current Alcohol Consumption Patterns

·         Average number of standard alcoholic drinks consumed per week: __ drinks per week

Type(s) of alcohol consumed (select all that apply)

·         Beer: Yes / No

·         Wine: Yes / No

·         Spirits or distilled alcohol beverages: Yes / No

Intensity and Duration of Alcohol Use

·         Heavy drinking episodes (≥4 drinks in one sitting): __ episodes per month

·         Years of regular alcohol use: __ years

·         Periods of abstinence lasting≥6 months (if applicable): Yes / No

Recreational Drug Use (past 12 months)

·         Cocaine: Yes / No

·         Methamphetamine: Yes / No

·         Ecstasy (MDMA): Yes / No

·         Non-medical opioids use: Yes / No

·         Non-medical use of stimulants or sedatives: Yes / No

·         Other substances (specify): __

·         Overall frequency of recreational drug use (any substance): __ times per month

Cannabis Product Types Used (select all that apply)

·         Smoked cannabis: Yes / No

·         Vaporized cannabis: Yes / No

·         Edible cannabis products: Yes / No

·         Cannabis oils, concentrates, or tinctures: Yes / No

Cannabis Use Patterns

·         Frequency of cannabis use: __ times per week

·         Total duration cannabis use: __ years

Primary residential location type (select one option)

·         Urban: Yes / No

·         Suburban: Yes / No

·         Rural: Yes / No

Type of Residence (select one)

·         Detached or semi-detached House: Yes / No

·         Condominium or apartment: Yes / No

·         Other residence type (specify): __

House Tenure (select one)

·         Owned residence: Yes / No

·         Rented residence: Yes / No

·         Duration of residence at current location: __ years

Outdoor Environmental Exposure

·         Average daily time spent outdoors: __ minutes per day

·         Approximate distance from residence to major roadways or highways: __ meters

Outdoor Air Quality Exposure (if known)

·        Use of air-quality alerts or monitoring tools (e.g., indoor air quality monitors, local smog or wildfire smoke alerts, radon testing devices): Yes / No

·        Residence located near industrial or pollution sites (e.g., power plant, mining operations, cement plants, airports, refineries): Yes / No

·         Proximity to green spaces (e.g., parks, forests, natural areas): __ meters

Indoor Air Quality and Ventilation

·         Use of mechanical ventilation or air exchange systems: Yes / No

·         Use of indoor air purifiers: Yes / No

Primary Drinking Water Source (select all that apply)

·         Municipal water supply: Yes / No

·         Private well water: Yes / No

·         Bottled water: Yes / No

Use of Water Filtration System

·         Activated carbon filter: Yes / No

·         Reverse osmosis system: Yes / No

·         Other filtration system (specify): __

Average Night time Noise Level

·         Quiet (minimal or no disruptive noise): Yes / No

·         Moderate (intermittent or background noise): Yes / No

·         Loud (frequent or disruptive noise): Yes / No

Artificial Light Exposure at Night:

·        Exposure to outdoor or indoor artificial light sources during night-time (e.g., streetlight LEDs, electronic screens, indoor lighting): Yes / No

Bedroom Light Conditions During Sleep

·         Complete darkness: Yes / No

·         Low light ambient light present: Yes / No

·         Moderate or bright light present: Yes / No

Spiritual or Religious Practices

·         Participation in spiritual or religious activities (if applicable): Yes / No

·         Average weekly time spent in spiritual or religious practices (prayer, meditation, worship services): __ minutes per week

·         Membership in a formal religious or spiritual community (e.g., congregation, meditation group, faith-based organization): Yes / No

·         Years of involvement in the current spiritual or religious tradition: __ years

Sense of Purpose, Values, and Meaningful Engagement

·         Active engagement in activities aligned with personal goals, core values, or life purpose: Yes / No

·         Average weekly time devoted to purpose-driven activities
(e.g., creative work, mentoring, advocacy, mission-driven projects): __ hours per week

Altruism, Volunteerism, and Community Engagement

·         Participation in volunteer or altruistic activities: Yes / No

·         Average number of volunteer or community service events per month: __ events per month

·         Average weekly time devoted to volunteer or community service activities: __ hours per week

·         Number of charitable, non-profit, or community organizations supported (financially, logistically, or through service): __ organizations

Social and Emotional Contribution Indicators

·         Average weekly hours providing unpaid support or assistance (e.g., family members, neighbors, friends, or community members): __  hours per week

·         Care giving duties performed per month (e.g., childcare, elder care, disability support, mentorship, or tutoring): __ duties per month

Personal Growth and Self-Development Activities

·         Number of structured personal development activities completed in the past 12 months (e.g., professional or personal growth workshops; seminars or conferences; structured coaching or therapy programs; skills-based training programs; guided self-study curricula): __ items per year

·         Average weekly time devoted to intentional personal growth activities (e.g., education, reading, reflective bogs and articles, reflective writing or journaling, personal development reading, online courses or learning platforms, guided coaching, skill-building exercises): __ hours per week

Mentorship and Guided Development

·         Currently serving as a mentor: Yes / No

·         Currently participating as a menthe: Yes / No

·         Total years of participation in formal or informal mentorship relationships: __ years

Goal Pursuit and Value Alignment

·         Number of long-term personal or professional goals currently being pursued: __ goals

·         Number of goals achieved in the past five (5) years: __ goals

·         Use of formal goal setting or planning systems (e.g., written plans, digital tools, coaching frameworks): Yes / No

Autonomy and Life Navigation

·         Number of major independent decisions made in the past 12 months (e.g., education, career, finances, health): __ decisions per year

·         Number of major life transitions managed independently across the lifespan (e.g., relocation, career change, educational milestones): __ transitions

Mastery and Expertise Development

·         Primary area of expertise or mastery focus (e.g., education, healthcare, information technology, finance, scientific research, creative arts, athletics) (specify): __

·         Total number of years devoted to developing the primary area of expertise: __ years

·         Number of domains in which advanced or professional-level competence has been attained: __  domains

Diagnostic and Laboratory Tests

Most objective and quantifiable signals of systemic physiological health

1. Blood Panels and Biomarkers

Instructions for Reporting Blood Test Results

1.    Report the most recent blood test results directly from the original laboratory report. Clearly specify the blood panels and associated blood biomarkers measured.

2.    Record the exact units of measurement and values as provided by the laboratory (e.g., mol/L, mg/do, mol/L, µg/L, pg/mL).

3.    Each blood biomarker are to be reported once only within this assessment, regardless of whether it appears on multiple laboratory panels.

4.    You also can transfer, transcribe, or paste all blood test results in the BOX below.

Examples of Commonly Used Blood Panels and Biomarkers

General Chemistry

·         Fasting glucose: __

·         Haemoglobin A1c/Total Haemoglobin: __ % (or mol/mol)

·         Sodium: __ mol/L

·         Potassium: __ mol/L

·         Créatinine: __ µmol/L (SI unit)

·         Glomerular Filtration Rate (eGFR): __ KL

·         C-reactive protein (CRP): __ mg/L

Lipids Profile

·         Triglycerides: __ mol/L

·         Cholesterol: __ mol/L

·         HDL Cholesterol: __ mol

·         Non-HDL Cholesterol: __ mol/L

·         LDL Cholesterol: __ mol/L or mg/do

·         Cholesterol/HDL Ratio: __  (unitless)

Other  Metabolic Blood Biomarker Panels Related to Cells and Organ-System

·         Cardio-metabolic Function and Risk Biomarkers

·         Endocrine Pancreatic Function (Glucose and Insulin Regulation)

·         Liver Function and Hepato cellular Integrity Biomarkers

·         Endocrine and Hormonal Markers

·         Viral Hepatitis Serologic Status (detection and immunity)

Nutritional and Micronutrient Status Panel

This blood panel encompasses biomarkers that assess circulating levels of essential and conditionally essential (dispensable) nutrients. These biomarkers are conventionally grouped to evaluate overall nutritional adequacy, micronutrient status, and nutrient-related physiological function.

Urinalysis Chemical

Guidelines for Reporting:

1.    Report on the collection date and time and transcribe all urinalysis findings exactly as stated in the original laboratory report.

2.    Urinalysis results may be presented as negative/trace/positive or using semi-quantitative grades (e.g., 1+, 2+, 3+).

3.    Record available test results in the blank field following the colon (:).

·         Leucocytes:

·         Protein:

·         Blood:

·         Glucose:

·         Ketones:

·         Leukocyte Esterase:

·         Other urine test results (specify):

Random Urine Chemistry (Albumin Creatinine Ratio)

·         Albumin (urine): __ mg/L

·         Creatinine (urine): __ mnol/L

·         Albumin (urine): __ mg/mol

General Reporting Instructions

1.     Record available test results in the blank field following the colon (:).

2.     Report the findings exactly as stated in the original laboratory or clinical report.

3.     Include the exact name of the test, the date of testing, specimen type, and testing method, if provided.

4.     Record quantitative values with units (e.g., µg/g, ng/mL, mol/L) where applicable.

Stool-Based Diagnostics

·         Comprehensive stool analysis (e.g., microbiome composition):__

·         Short-chain fatty acids (SCFAs):

·         Digestive enzyme activity (e.g., pancreatic elastase): __

·         Pathogens, parasites, and dysbiosis indices: __

Hair-Based Diagnostics

·         Mineral and trace element analysis: __

·         Long-term exposure to heavy metals (e.g., mercury, lead): __

·         Retrospective assessment of nutrient and toxin exposure patterns: __

Saliva-Based Diagnostics

·         Diurnal cortisol rhythm (hypothalamic–pituitary–adrenal axis assessment):

·         Sex hormone profiling (free hormone fractions): __

·         Salivary immunoglobulin A (IgA; mucosal immune function): __

·         Other integrated functional and specimen-based tests (specify): __

3. Tumor and Cancer Biomarkers

Guidelines for Reporting:

For each tumor and cancer biomarker listed below, transcribe the results exactly as reported by the testing laboratory. Record the results in the blank field after the (:) The empty space after the colon (:) is the data-entry field.

1.    The measured laboratory value, including the unit of measurement.

2.    The laboratory-provided reference range, adjusted for age and sex where applicable/

3.    A brief categorical interpretation, selected from the following options: within reference range, elevated, or decreased reference range, elevated, or decreased.

·         Total PSA (Prostate-Specific Antigen): __

·         CA 15-3 / CA 27.29 (breast cancer): __

·         CA-125 (Cancer Antigen 125) (ovarian cancer): __

·         Chromogranin A (CgA) (neuroendocrine tumors): __

·         Other tumor and/or cancer biomarkers (specify): __

4. Neurophysiological and Sensory Function Assessment

General Reporting Guidelines

1.    Record the exact name of the test, the test date, and testing modality, if available.

2.    Transcribe quantitative values, reference ranges, and categorical outcomes verbatim from the source report.

3.    Use standard clinical units where applicable (e.g., ms, µV, bpm, dB HL, events/hour).

·         Electroencephalography (EEG):

·         Electrocardiography (ECG) and ambulatory Holter monitoring:

·         Electromyography (EMG) and nerve conduction studies:

·         Sleep studies (polysomnography):

·         Audiometry and visual field testing:

Imaging and Ultrasound

Objective structural and organ-level data used in biological age estimators.

Guidelines for Reporting Imaging and Diagnostic Test Results

1.     Record all imaging and diagnostic test results verbatim, exactly as stated in the official radiology or imaging report (e.g., ultrasound, CT, MRI, PET, DXA/DEXA).

2.     For each entry, clearly document the name of the imaging or diagnostic test and the date of the report.

3.     Enter the results in the blank field following each colon (:) The blank field after the colon is for the direct transfer, transcribe, or copy-and-paste of imaging report findings.

4.     OR, you may also transfer, transcribe, or copy-and-paste of imaging report findings

Vascular Aging

·         Carotid intima–media thickness (CIMT) ultrasound: __

·         Coronary calcium score (CT): __

·         Arterial stiffness (PWV – pulse-wave velocity): __

·         Aortic duplex ultrasonography: __

·         Other vascular assessments:(specify): __

Organ Health

·         Liver ultrasound or Fibro Scan: __

·         Abdominal ultrasound: __

·         Kidney ultrasound: __

·         Echocardiogram (heart structure and function): __

·         Thyroid ultrasound (nodularity): __

Body Composition (Quantitative Metrics)

·         Body fat percentage: __ %

·         Lean body mass: __ kg or __ % (if available)

Measurement Method (select one):

·         Visceral fat level: (DEXA score): __ % or index value

·         Bone mineral density (BMD) T-score or Z-score (specify): __

·         Bioimpedance (BIA) for hydration and lean mass trends:

·         Other measurement methods, if avaiable (specify): _

Additional Imaging and Diagnostic TestsTargeting Specific Organs

·         Cardiac MRI: __

·         Cardiac CT angiography (CCTA): __

·         Brain MRI (structural):  __

·         Renal CT or Renal MRI:  __

·         Adrenal CT/MRI: __

·         Other imaging or diagnostic studies (specify): __

Clinical and Medical History

Diagnoses and interventions shaping health status and biological aging trajectories

Basic Body Measurements

·         Height: __ cm or __ inches

·         Weight: __ kg or __ lb.

·         Body Mass Index (BMI) __ kg/m²

Circumference Measurements

·         Waist circumference: __ cm or inches

·         Hip circumference: __ cm or inches

·         Waist-to-hip ratio (WH R): __

·         Neck circumference (used in obstructive sleep apnea risk models): __ cm / inches

Cardiometabolic Anthropometrics

·         Blood pressure: Systolic: __ mmHg  / Diastolic: __ mmHg

·         Resting heart rate (RHR): __ beats per minute (bpm)

·         Heart rate variability (HRV - 7-day rolling average): __ ms

Weight Stability and Weight History (specify kg or lb)

·         Net weight change in the past 12 months: __ kg gained or __ kg lost

·         Number of weight fluctuations≥5 kg or 10 lbs in the past 5 years: __ fluctuations

·         Highest adult weight (≥ age 16):__ kg or lb.

·         Lowest adult weight (after age 18): __ kg or lb.

·         Duration at current weight range (±3 kg): __ years

·         Other clinically relevant body composition indicators (specify): __

2. Chronic Conditions (Diagnosed Conditions Only)

Reporting Guidelines

For each of the “Yes” or “No” option listed below:

1.     Select “Yes” if the condition option currently applies to you.

2.     Select “No” if the option does not apply to you.

3.     Leave both “Yes” and “No” unselected if the condition is not applicable.

NB: Items left unselected will be recorded as not applicable (NA) and will be excluded from scoring and subsequent statistical analysis.

Cardiovascular

·         Hypertension: Yes / No - Age of onset: __

·         Coronary artery disease: Yes / No

·         Myocardial infarction (heart attack): Yes / No

·         Heart failure: Yes / No

·         Atrial fibrillation (AFib) or arrhythmia: Yes / No

·         Other heart-related disease (specify): Yes / No

Metabolic

·         Prediabetes: Yes / No

·         Type 2 diabetes: Yes / No - Age of onset__

·         Hyperlipidemia: Yes / No

Endocrine / Hormonal

·         Thyroid disease (hypo/hyperthyroidism or hyperthyroidism): Yes / No

·         Polycystic ovary syndrome (PCOS): Yes / No

·         Menopause: Yes / No - Age of onset:  __

·         Diagnosed low testosterone: Yes / No

Immune / Autoimmune

·         Autoimmune disease (specify): __

·         Chronic viral infections (e.g., HBV or HCV): __

·         Other immune or autoimmune diagnosed conditions (specify): __

Respiratory

·         Asthma: Yes / No

·         Chronic Obstructive Pulmonary Disease (COPD): Yes / No

·         Other respiratory diagnosed conditions (specify): __

Musculoskeletal

·         Osteoporosis: Yes / No

·         Diagnosed sarcopenia: Yes / No

·         Other diagnosed musculoskeletal condition(s) (specify): __

Gastrointestinal

·         Gastroesophageal reflux disease (GERD): Yes / No

·         Celiac disease: Yes No

·         Inflammatory bowel disease (Crohn or ulcerative colitis): Yes / No

·         Other gastrointestinal diagnosed conditions (specify): __

Neurological

·         Stroke or transient ischemic attack (TIA): Yes / No

·         Epilepsy: Yes / No

·         Other diagnosed neurological conditions (specify): __

3. Vaccination Status and Immunization (Vaccine-Specific)

Indicate whether each vaccination is up to date

Instructions: For each item, select one response

·       MMR (measles, mumps, rubella: immune or vaccinated: Yes / No

·       Tdap - Td booster, tetanus, diphtheria, pertussis; within past 10 years: Yes / No

·        Hepatitis A or Hepatitis (specify): Yes / No

·        Pneumococcal vaccine (if indicated by age/risk): Yes / No

·        Shingles vaccine (Shingrix: if indicated by age/risk): Yes / No

·       Travel vaccine (if applicable in past 5 years: Yes / No

·        Other vaccines (specify type(s)): __

·         Cancer diagnosis (type and year): __

·         Surgical history (list all surgeries and year performed): __

·         Organ transplant: Yes / No __ Type: __ Year: __

·         Fractures requiring medical treatment: Yes / No

·         Peptic ulcer disease (gastric or duodenal ulcers): Yes / No

·         Hospitalizations (number in the past 10 years): __

·         Intensive Care Unit (ICU) admissions: Yes / No  -  Year(s): __

·         Sexually transmitted infections (e.g., syphilis, gonorrhea) (specify):

·         Viral, bacterial, or parasitic infectious diseases (e.g., shingles, HIV, pneumonia, tuberculosis, meningitis) (specify): __

·         Other past medical diagnoses, surgeries, and hospitalizations (specify): __

Reporting Guidelines:

1.    Report all current prescription medications in use at the time of assessment.

2.    For each medication, record the generic or brand name, dose, and frequency in the blank field after the (:)

3.    If no medications are currently used, leave the space following the colon blank;/

     Unanswered fields will be recorded as not applicable (NA).

·         Cardiovascular medications (e.g., antihypertensives, lipid-lowering agents, antiarrhythmics: __

·         Antidiabetic medications (e.g., insulin, metformin, GLP-1 receptor agonists, SGLT2 inhibitors): __

·         Thyroid medications (e.g., levothyroxine, antithyroid agents): __

·         Anticoagulant and antiplatelets agents (e.g., warfarin, direct oral anticoagulants, aspirin when prescribed): __

·         Anti-inflammatory agents and corticosteroids (systemic or long-term use): __

·         Immunosuppressive medications (e.g., biologics, disease-modifying agents): __

·         Hormone therapy: (e.g., hormone replacement therapy, testosterone therapy, contraceptive hormones): __

·         Analgesics prescribed for chronic pain(e.g., opioids, neuropathic pain agents): __

·         Others prescription medications (specify conditions and medication[s]): __

6. Dental Care Utilization and History

·         Frequency of professional dental cleanings (select one)

Once a year: Yes / No

Less than twice per year: Yes / No

Less than ounce every 2 years: Yes / No

·         History of periodontal treatment (e.g., scaling and root planning): Yes / No

·         Use of antibiotics for dental infections in the past 5 years: Yes / No

·         Use of dental prosthetics (crowns, bridges, dentures): Yes / No

Diagnosed Dental and Periodontal Conditions

·         Recurrent dental caries despite treatment: Yes / No

·         Gingivitis (gum inflammation): Yes / No

·         Periodontitis (mild, moderate, or severe): Yes / No

·         Other periodontal conditions (specify): __

Oral and Mucosal Conditions

·         Oral ulcers or recurrent aphthous stomatitis: Yes / No

·         Oral candidiasis (thrush): Yes / No

·         Chronic oral inflammation or mucosal lesions (other): Yes / No

Overall ability to manage psychological stress (select one)

·         Effective: Yes / No

·         Moderately effective: Yes / No

·         Ineffective: Yes / No

Emotional State Frequency

·         Frequency of feeling calm and emotionally balanced: __ times per week

·         Frequency of anxiety symptoms (e.g., excessive worry, restlessness, muscle tension): __ times per week

·         Frequency of depressive-type symptoms (e.g., low mood, reduce interest or pleasure, fatigue): __ times per week

·         Frequency of emotional and volatility or mood swings: __ episodes per week

Perceived effectiveness of coping strategies during periods of stress (select one)

·         Effective: Yes / No

·         Moderately effective: Yes / No

·         Not effective: Yes / No

Emotional Awareness and Regulation

·         Average duration rumination or intrusive thought duration: __ minutes per day

·         Number of days per week on which mood is negatively affected by poor sleep:__ days per week: __

·         Sleep disruption attributable to emotional stress: __ nights per week

·         Use of intentional regulation strategies (e.g., mindfulness, cognitive reframing, breathing techniques): Yes / No

8. Clinical Mental Health History (Lifetime)

Reporting Guidelines

For each of the “Yes” or “No” option listed below:

1.     Select “Yes” if the condition option currently applies to you.

2.     Select “No” if the option does not apply to you.

Unselected items will be recorded as not applicable (NA).

Diagnosed Anxiety Disorder(s)

·         Generalized Anxiety Disorder (GAD): Yes / No

·         Social Anxiety Disorder (Social Phobia): Yes / No

·         Separation Anxiety Disorder (SepAD): Yes / No

·         Other diagnosed anxiety disorders (specify): __

Diagnosed Depressive Disorder(s)

·         Bipolar spectrum disorder: Yes / No

·         Post-partum depression: Yes / No

·         Other diagnosed depressive disorders (specify): __

Diagnosed Mental or Neuropsychiatric disorder(s)

·         Attention-Deficit/Hyperactivity Disorder (ADHD): Yes / No

·         Post- traumatic stress disorder (PTSD): Yes / No

·         Obsessive-Compulsive Disorder (OCD): Yes / No

·         Other diagnosed mental or neuropsychiatric disorders (specify):

Current treatment and Therapeutic Interventions

·         Current psychiatric medications: (list all): __

·         Current engagement in psychotherapy or counseling: Yes / No

If yes, type (e.g., CBT, psychodynamic, trauma-focused): __

Neurocognitive and Psychological Testing (If available)

·         Montreal Cognitive Assessment (MoCA) score: ______ /30

·         Other standardized psychological or neurocognitive assessments completed: Yes / No

If yes, specify test(s) results and year: __

9. Diagnosed Sleep and Insomnia Disorders

Sleep-Related Breathing Disorders

·         Obstructive sleep apnea (OSA): Yes / No

Central Disorders of Hyper-somnolence

·         Narcolepsy (Type 1 or Type 2): Yes / No

·         Idiopathic hypersomnia or other hypersomnia disorder: Yes / No

·         Excessive daytime sleepiness despite adequate sleep duration: Yes / No

Current or Past Medications for the Treatment of Sleep Disorders

·         Non-benzodiazepine hypnotics (Z-drugs): Yes / No

·         Benzodiazepines: Yes / No

·         Melatonin receptor agonists: Yes / No

·         Other prescribed sleep-medications: Yes / No

If yes, specify: __

Medications for Narcolepsy and Hypersomnia

·         Wake-promoting agents: Yes / No

·         Sodium oxybate or related formulations: Yes / No

·         Other Medications for narcolepsy and hypersomnia: Yes / No

Movement-Related Sleep Disorders

·         Restless legs syndrome (RLS): Yes / No

·         Periodic limb movement disorder (PLMD): Yes / No

·         Sleep-related bruxism (teeth grinding): Yes / No

Medications for RLS and Movement Disorders

·         Dopamine agonists: Yes / No

·         Alpha-2-delta ligands: Yes / No

·         Other medications for RLS and Movement Disorders. Yes / No

If yes, specify: __

10, OPTIONAL - Family and Parental Medical History (First-Degree Relatives) Reporting Guidelines

1.    Report objective, diagnosed conditions only, of biological parents,

2.    Indicate Yes / No / Unknown

3.    The age at diagnosis and the age at death (where applicable).

Mother

·         Year of birth:

Mother’s Inherited Health Conditions

·         Hypertension: Yes / No – Age at diagnosis: __

·         Type 2 diabetes: Yes / No  – Age at diagnosis: __

·         Coronary artery disease / myocardial infarction: Yes / No  – Age at diagnosis: __

·         Thyroid disease (hypo/hyper): Yes / No – Age at diagnosis: __

·         Chronic kidney disease: Yes / No  – Age at diagnosis: __

·         Other inherited health conditions (specify): __

Mother’s Cancer History

·         Cancer diagnosis: Yes / No / Unknown

·         Type: __

·         Age at diagnosis: __

Mother’s Neurological Disorders

·         Alzheimer’s disease or other dementia: Yes / No  – Age at diagnosis: __

·         Parkinson’s disease: Yes / No  –  Age at diagnosis: __

·         Other neurological disorder (specify): __

Mother’s Longevity and Mortality Indicator

·         Age at death if deceased: __

·         Cause of death (if deceased): __

Father

·         Year of birth

Father’s Inherited Health Conditions

·         Hypertension: Yes / No  – Age at diagnosis: __

·         Type 2 diabetes: Yes / No  – Age at diagnosis: __

·         Coronary artery disease / myocardial infarction: Yes / No – Age at diagnosis: __

·         Heart failure / cardiomyopathy: Yes / No  – Age at diagnosis: __

·         Chronic kidney disease: Yes / No  – Age at diagnosis: __

·         Other inherited health conditions (specify): __

Father’s Cancer History

·         Cancer diagnosis: __

·         Type: __

·         Age at diagnosis: __

D. Father’s Neurological Disorders

·         Alzheimer’s disease or other dementia (specify): Yes / No – Age at diagnosis: __

·         Parkinson’s disease: Yes / No – Age at diagnosis: __

·         Other neurological disorder (specify): __

Father’s Longevity and Mortality Indicator:

·         Age at death if deceased: __

·         Cause of death (if deceased): __

Genomic and Epigenetic Markers

Inherited DNA variants that influence biological pathways, disease risk, and aging

Guidelines for Reporting Genomic Biomarkers:

1.    For each genomic biomarker listed below, indicate whether prior genetic testing has identified the specified variant by entering “Yes”or“No” in the space provided after the colon (:).

2.    If yes, specify the gene name, variant, genomic locus (if available), genotype and zigocity, reference allele and risk allele (if stated), and Clinical classification (if provided by the testng laboratory)]

3.    Do not reinterpret, summarize, or infer clinical significance beyond what is explicitly reported in the original laboratory documentation.

All genomic markers tests may be reported verbatim in the BOX below

1. Single-Nucleotide Polymorphisms (SNPs) Affecting Metabolic and Disease Risk

One-Carbon Metabolism and Methylation

Variants influencing folate metabolism, homocysteine regulation, and DNA methylation capacity

·        MTHFR (C677T, A1298C) (Variants associated with reduced folate bioactivation, elevated homocysteine-concentrations, and impaired DNA methylation, conferring increased risk for cardiovascular disease, pregnancy complications, neuropsychiatric vulnerability, and impaired detoxification, particularly under conditions of low folate intake):

·        MTR / MTRR (Variants may impair vitamin B12–dependent remethylation of homocysteine to methionine, increasing risk of hyperhomocysteinemia, megaloblastic anemia, neurological dysfunction, and cardiovascular disease, with downstream effects on global methylation capacity):

·        SHMT1 (Variant ssociated with altered serine–glycine–folate flux, potentially affecting nucleotide synthesis and DNA repair, and have been inked to increased susceptibility to neural tube defects, certain cancers, and methylation imbalance, particularly when folate availability is suboptimal):

·         Other variants that affect folate metabolism, homocysteine regulation, and DNA methylation capacity that increase the risk of cardiovascular disease, cognitive and neuropsychiatric vulnerability, or impaired epigenetic regulation (specify):

Lipid Metabolism and Neurodegenerative Risk

Variants influencing lipid transport, cholesterol homeostasis, and neurodegenerative susceptibility

·         LDLR (Variants affecting low-density lipoprotein receptor function may impair LDL clearance, increasing risk of hypercholesterolemia, atherosclerotic cardiovascular disease, and cerebrovascular pathology, which indirectly elevates susceptibility to vascular cognitive impairment and mixed dementia phenotypes):

·         PCSK9 (Genetic variation alters LDL receptor degradation and cholesterol regulation, influencing plasma LDL cholesterol levels and downstream risk of cardiovascular disease, cerebrovascular events, and neurodegenerative vulnerability via lipid-mediated vascular and inflammatory pathways):

·         Other variants influencing lipid transport, cholesterol homeostasis, and neurodegenerative susceptibility (specify):

Glucose Regulation and Insulin Sensitivity

Variants influencing glucose homeostasis and type 2 diabetes risk

·       TCF7L2 (Variants are strongly associated with impaired insulin secretion, altered incretin signaling, and increased risk of type 2 diabetes mellitus, particularly through effects on pancreatic β-cell function):

·       SLC2A2 (GLUT2) (Genetic variation may affect glucose transport across hepatocytes and pancreatic β-cells, influencing glucose sensing, fasting glucose levels, and susceptibility to dysglycemia and type 2 diabetes):

·        IRS1 (Variants influencing insulin receptor signaling efficiency are associated with insulin resistance, impaired glucose uptake, and increased risk of type 2 diabetes and related metabolic syndrome features.

·         Other Variants influencing glucose homeostasis and type 2 diabetes risk (specify):

2.Epigenetic Biomarkers (Biological Age Estimation)

Dynamic markers reflecting gene expression regulation and aging rate

DNA methylation–based epigenetic clocks quantify systematic age-related changes in gene regulation and are strongly associated with biological aging, chronic disease risk, and all cause mortality. These measures frequently outperform chronological age in predicting health outcomes and longevity.

·        Horvath Clock (A pan-tissue estimate of biological age associated with global epigenetic aging, multisystem disease risk, and longevity):

·        Hannum Clock (A blood-based estimate of hematologic and immune aging associated with cardiovascular disease, metabolic risk, and inflammation):

·        PhenoAge (An integrative measure combining DNA methylation patterns with clinical biomarkers to estimate phenotypic aging, associated with multimorbidity, frailty, and all-cause mortality):

·      GrimAge (A DNA methylation-based estimator associated with mortality risk, cardiovascular disease, cancer, and accelerated biological aging, reflecting cumulative exposure to damaging biological processes):

Telomere Biology

Markers of genomic stability and replicative aging

Telomere length and telomere attrition reflect cellular replicative history, oxidative stress exposure, and genomic stability, and are associated with aging, chronic disease susceptibility, and mortality

Telomere length and telomere attrition reflect cellular replicative history, cumulative oxidative stress exposure, and genomic stability, and are associated with biological aging, chronic disease susceptibility, and mortality risk.

·        Leukocyte Telomere Length (qPCR) (Associated with systemic biological aging, cardiovascular disease risk, immune senescence, and cumulative stress exposure):

·        Terminal Restriction Fragment (TRF) (Analysis provides absolute telomere length estimates; associated with replicative aging and longevity phenotypes):

·        Flow-FISH (A cell-type–specific telomere measurement technique associated with immune aging, hematologic disorders, and inherited telomere syndromes):

·        Telomere attrition rate  (longitudinal) (Reflects rate of biological aging, cumulative stress burden, and disease progression risk):

·        Other telomere methods capturing tissue-specific or high-resolution telomere dynamics (specify):

Microbiome-Related Molecular Markers

Functional genomic interface between environment and host biology

Gut microbiome composition and function influence metabolic regulation, immune signaling, neuroinflammation, and biological aging, acting as a dynamic and modifiable contributor to overall health.

·         Alpha diversity indices (Associated with metabolic resilience, immune stability, and reduced chronic disease risk):

·         Butyrate-producing taxa (e.g., Faecalibacterium, Roseburia) (Linked to gut barrier integrity, anti-inflammatory signaling, insulin sensitivity, and healthy aging):

·         Pathobiont overgrowth (Associated with chronic inflammation, metabolic dysfunction, gastrointestinal disorders, and neuroimmune dysregulation):

·         Short-chain fatty acid (SCFA) concentrations (Reflect microbial metabolic output; associated with immune modulation, glucose regulation, lipid metabolism, and epigenetic signaling):

3,Genomic Biomarkers for Dementia and cognitive Decline.

Gene-based loci in which specific variants, alleles, or repeat expansions confer disease risk or directly cause neuropathology. A locus (plural: loci) refers to a defined physical location on a chromosome where a gene or genetic marker reside

·         APP, PSEN1, PSEN2 (Associate with early onset familial Alzheimer’s disease ( EOAD):

·         APOE ε2/ε3/ε4 [Alzheimer’s disease (late-onset Alzheimer’s disease (LOAD):

·         NOTCH3, HTRA1, COL4A1, COL4A2 [Associated with vascular cognitive impairment / Vascular Cognitive Impairment (VCI) and vascular dementia]

·        C9orf72 repeat expansion, GRN, MAPT  (Associate with frontotemporal dementia (FTD)]

·         Other genomic markers related to dementia and cognitive decline (specify gene, locus, and variant): __

4. Genomic Markers related to Psychological/Psychiatric Disorders

Depressive Disorders (e.g., Major Depressive Disorder, etc.)

·        SLC6A4 ( Serotonin transporter gene; regulating serotonin reuptake and serotonergic neurotransmission):

·        BDNF (rs6265) (Encodes brain-derived neurotrophic factor, a key regulator of synaptic plasticity, neurogenesis, and learning):

·        FKBP5 (Encodes a co-chaperone protein that modulates glucocorticoid sensitivity and stress response regulation):

Anxiety Disorders (GAD, panic disorder, phobias, and so on)

·         FKBP5 (Regulates glucocorticoid receptor sensitivity and hypothalamic-pituitary- adrenal (HPA) axis reactivity):

·         CRHR1 (Encodes the corticotropin-releasing hormone receptor influencing stress responsivity and fear conditioning):

·         SLC6A4 (Genetic variation affecting serotonin reuptake efficiency, emotional regulation, and anxiety sensitivity):

Trauma- and Stressor-Related Disorders (PTSD)

·         FKBP5 (Modulates stress reactivity and trauma-related vulnerability via HPA axis feedback mechanisms):

·         ADCYAP1R1 (Encodes the PACAP receptor involved in neuroendocrine stress signaling and fear-response regulation):

·         NR3C1 (Encodes the glucocorticoid receptor, a central regulator of cortisol signaling and stress adaptation):

Obsessive-Compulsive and Related Disorders (OCD)

·         SLC1A1  (Glutamate transporter gene associated with obsessive compulsive symptomatology)

·         GRIN2B (Encodes an NMDA receptor subunit critical for synaptic plasticity, learning, and excitatory signaling):

·        HTR2A (Encodes serotonin 2A receptor involved in cognitive control, mood regulation, and behavioral flexibility):

Neurodevelopmental Disorders [Autism Spectrum Disorder (ASD)]

·        CHD8 (Chromatin-remodeling gene regulating gene expression during early brain development):

·        SHANK3 / SHANK2 (Encode postsynaptic scaffold proteins essential for synapse formation, organization, and excitatory synaptic signaling):

·        SCN2A (Encodes a voltage-gated sodium channel critical for neuronal excitability and early cortical network development):

Personality Disorders (Frequently studied candidate systems)

·        SLC6A4, HTR2A (Serotonergic signaling involved in emotional regulation, impulsivity, and interpersonal sensitivity):

·        DRD2, DRD4, COMT (Dopamine pathways influencing reward processing, novelty seeking, and behavioral control):

·        FKBPS (Stress axis; regulation affecting glucocorticoid receptor sensitivity and stress reactivity):

Feeding and Eating Disorders (Anorexia, Bulimia, Bulimia Nervosa, Binge Eating Disorders)

·    BDNF (Regulates neural plasticity, appetite control, and reward-relaated eating behavior):

·         HTR2A (Modulates serotonergic signaling involved in appetite regulation and mood–eating interactions):

·        HTR2A (modulates serotonergic signaling involved in appetite regulation, and mood–eating interactions):

·        DRD2 (Dopamine receptor gene central to reward processing and compulsive or binge-eating behaviors):

C) Intellectual developmental disorder

·         FMR1 (Associated with Fragile X syndrome; regulates synaptic development and plasticity):

·         MECP2 (Controls gene expression critical for neuronal maturation and synaptic function):

·         DYRK1A (regulates brain growth, neurodevelopment, and cognitive functioning):

·        SCN2A (Neuronal sodium channel essential for action potential firing and neurodevelopment):

·        SHANK3 (Postsynaptic structural protein required for excitatory synapse formation and cognitive development):

·         Other genomic markers related to psychological or psychiatric disorders (specify gene, locus, and variant tested): __

6. Genomic Markers Associated With Learning Disabilities

Dyslexia / Reading Disability (most studied)

·         DYX1C1 (DNAAF4) (Associated with phonological processing deficits, decoding accuracy, and reading fluency impairments):

·         DCDC2 (Associate with dyslexia-related deficits in orthographic processing, reading accuracy, and phonological decoding):

·         KIAA0319 (Linked to phonological processing deficits affecting word recognition and reading comprehension):

·         ROBO1 (Associate with auditory processing deficits and reduced reading fluency):

·         FOXP2 (Associate with developmental speech and language disorders, including verbal dyspraxia and grammatical processing impairments):

·         Other genes, genomic loci, copy number variants, or molecular markers associated with reading-related learning disabilities (specify gene name, locus, and variant):

Dyscalculia / Math Learning Disability

·        ROBO1 (Associated with numerical magnitude processing and visuospatial integration difficulties):

·        CNTNAP2 (Associated with mathematics learning difficulties mediated by language and executive-function impairments):

·        Other genes, genomic loci, copy number variants, or molecular markers associated with dyscalculia or mathematics-related learning disabilities (specify):

Written Expression Disorder / Dysgraphia

·         CNTNAP2 (Associated with language-based learning disabilities affecting written expression and spelling):

·         FOXP2 (Speech motor planning and expressive language impairments influencing writing acquisition):

·         CMIP (Associated with written language impairment involving phonological processing, reading comprehension, and verbal working memory):

·         Other genomic markers associated with written expression or dysgraphia (specify):